| 0.28 0.04 (16.67%) | 07-26 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.37 |
1-year : | 0.44 |
| Resists | First : | 0.32 |
Second : | 0.37 |
| Pivot price | 0.22 |
|||
| Supports | First : | 0.24 |
Second : | 0.2 |
| MAs | MA(5) : | 0.23 |
MA(20) : | 0.22 |
| MA(100) : | 0.41  |
MA(250) : | 2.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39 |
D(3) : | 26 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 12.23 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PXMD ] has closed above the upper band by 12.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 70.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.3 - 0.3 | 0.3 - 0.3 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.28 - 0.28 | 0.28 - 0.28 |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Fri, 12 Apr 2024
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - Benzinga
Wed, 22 Nov 2023
PaxMedica Announces Pricing of $7M Public Offering - Yahoo Finance
Tue, 31 Oct 2023
PaxMedica (NASDAQ: PXMD) to jump 1,700% today - purely nominal and technical - Dhaka Tribune
Tue, 31 Oct 2023
Paxmedica Inc (PXMD) Quote - Press Release - The Globe and Mail
Thu, 27 Jul 2023
Is PaxMedica Inc. Stock a Good Buy? - Benzinga
Mon, 15 May 2023
PaxMedica, Inc. Provides First Quarter 2023 Business - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 638 (K) |
| Shares Short P.Month | 552 (K) |
| EPS | 68.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -258.3 % |
| Return on Equity (ttm) | -975.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|